Biomaterials Science · 2020 · 26 citations · 29 references
MedicineOncologyPharmacologyCancer PharmacologyDrug DeliveryTumor MicroenvironmentCancer EpigeneticsCancer ImmunotherapyLiposomal FormulationsLiposome-based DeliveryLung Cancer PharmacotherapyTumor Microenvironment ModulationLiposomal Co-deliveryLiposomal NanocarriersLiposome-drug ConjugatesLiposomesNon-small Cell Lung Cancer ImmunotherapyNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentStimuli-responsive Liposomes
The tumor microenvironment (TME) and its major component tumor-associated macrophages (TAM) play a pivotal role in the development of non-small cell lung cancer (NSCLC). An epigenetic drug-based combinatory therapeutic strategy was proposed and a deformable liposome system (D-Lipo) was developed for vorinostat and simvastatin codelivery for remodeling the TME. The application of deformable liposomes in systemic cancer drug delivery has been underexplored and its potential in cancer therapy is largely unknown. This work revealed that D-Lipo exhibited an enhanced intratumor infiltration ability. The proposed therapeutic strategy was characterized by a chemo-free regimen and TME remodeling function. D-Lipo efficiently inhibited the growth of the xenografted lung tumor. The anti-tumor mechanisms involved the repolarization of TAM from the M2 to M1 phenotype, anti-angiogenesis, and the consequent TME remodeling. As a result, the amounts of the anti-tumor M1 macrophages and the cytotoxic CD8+ T cells increased, while the amounts of the pro-tumor M2 macrophages and regulatory T cells (Tregs) reduced. It provides a promising avenue for epigenetic drug-based combination therapy for treating solid tumors.
29
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron, Orianne Colussi, Elie Marcheteau et al. · The Journal of Experimental Medicine · 2015 · 1.2K citations · Full text
Medicine, Immunology, Oncology +17
Reciprocal regulation of inflammation and lipid metabolism by liver X receptors
Sean B. Joseph, Antonio Castrillo, Bryan Laffitte et al. · Nature Medicine · 2003 · 1.1K citations
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages
Jennifer L. Guerriero, Alaba Sotayo, Holly Ponichtera et al. · Nature · 2017 · 551 citations · Full text
Medicine, Oncology, Pharmacology +12